S201: Synthetic Biology meets Terpenes: What’s after Artemisinin?

Thursday, July 28, 2011: 3:30 PM
Oak Alley, 4th fl (Sheraton New Orleans)
Jack Newman, Amyris Biotechnologies, Emeryville, CA
The field of synthetic biology means many things to many people. Amyris has developed a synthetic biology platform that is defined by the ability to rapidly construct microbes and test their ability to make chemical compounds.  At the heart of this construction platform is a modular molecular biology system of DNA construction that allows the automated assembly of DNA constructs from an established and expandable library.  96-well plate cultivation and high-throughput screening allows the construction of well over 10’s of thousands of new strains per month as well as the accurate screening for production levels.  This talk will briefly recap the Automated Strain Engineering (ASE) platform and focus on the Terpene products made via ASE.

The foundations of the ASE platform were built to attain a strain of yeast that could produce 25 g/L of the terpene Artemisinic acid for the production of low-cost and abundant Artemisinin, an anti-malarial drug.  Having achieved those goals and begun commercialization and manufacturing of artemisinin, we now describe the use of this platform to produce fuel molecules, lubricants, emollients and fragrances.  This talk will touch on the production of each of these molecules, which are terpenes or derivatives of terpenes.  In particular, we will focus on the production and use of farnesene and it’s derivative Squalane, a terpene that has been used as a lubricant for fighter planes as well as an emollient for skin therapeutics.  Squalane has traditionally been sourced from the livers of Squalus genus of dogfish sharks and the fishing of these sharks for such uses has led to their precipitous decline.  Alternative sources were investigated deeply when Europe banned the use of Squalane obtained from sharks.  Asia continues to use sharks as a source of squalane.  Synthetic biology presents an attractive alternative to shark sources of squalene and has been the first ‘for-profit’ product sold by Amyris, as Artemisinin remains an entirely non-profit product.